Drug Type Small molecule drug |
Synonyms WXFL 10203614, WXFL-10203614, WXFL10203614 |
Target |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 3 | China | 31 Aug 2023 | |
Crohn's disease, active moderate | Phase 2 | China | 25 Oct 2024 | |
Crohn's disease, active severe | Phase 2 | China | 25 Oct 2024 | |
Moderate Atopic Dermatitis | Phase 2 | China | 16 Oct 2024 | |
Severe Atopic Dermatitis | Phase 2 | China | 16 Oct 2024 | |
Ulcerative colitis, active moderate | Phase 2 | China | 13 Sep 2024 | |
Ulcerative colitis, active severe | Phase 2 | China | 13 Sep 2024 |
Phase 1 | - | 80 | ulovhxqcqx(viadmiksmd) = All adverse events (AEs) were mild or moderate and resolved spontaneously. mzmuepfzca (ybjulhzlmo ) | Positive | 04 Nov 2022 |